Across TCGA pan-cancer cohorts, PLCG2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PLCG2 data layer compared with 19 for mass-spec protein and 8 for mutation status.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PLCG2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PLCG2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.
LUAD, PDAC, and GBM are the cancer types where PLCG2 mass-spec protein most reproducibly stratifies survival.
mass-spec protein survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.